NVS - Novartis AG
NYSE
->
Healthcare
->
Drug Manufacturers—General
Basel,
Switzerland
Type: Equity
NVS price evolution
NVS
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $9694 | $14428 | ||
| Short term investments | $2759 | $2016 | ||
| Net receivables | $8251 | $7533 | ||
| Inventory | $5743 | $5913 | ||
| Total current assets | $26447 | $30481 | ||
| Long term investments | $67887 | $69464 | ||
| Property, plant & equipment | $10542 | $10924 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $94334 | $99945 | ||
| Current liabilities | ||||
| Accounts payable | $4062 | $4926 | ||
| Deferred revenue | ||||
| Short long term debt | $8564 | $6314 | ||
| Total current liabilities | $29288 | $26390 | ||
| Long term debt | $18720 | $20034 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $54659 | $53278 | ||
| Shareholders' equity | ||||
| Retained earnings | $38899 | $45883 | ||
| Other shareholder equity | -$3608 | |||
| Total shareholder equity | $39675 | $46667 | ||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 2 Feb 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3207 | $2877 | $28329 | $9658 |
| Short term investments | $2016 | $1869 | $1895 | $1746 |
| Net receivables | $9376 | $9894 | $8828 | $9963 |
| Inventory | $5913 | $7175 | $6666 | $7131 |
| Total current assets | $30481 | $36910 | $45718 | $29673 |
| Long term investments | $69464 | $80543 | $86077 | $11611 |
| Property, plant & equipment | $10924 | $12195 | $11545 | $13939 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $102386 | |||
| Total investments | ||||
| Total assets | $99945 | $117453 | $131795 | $132059 |
| Current liabilities | ||||
| Accounts payable | $4926 | $5146 | $5553 | $5403 |
| Deferred revenue | ||||
| Short long term debt | $6314 | $6127 | $6502 | $2466 |
| Total current liabilities | $26390 | $28656 | $30208 | $33059 |
| Long term debt | $20034 | $21782 | $24523 | $26259 |
| Total noncurrent liabilities | $42334 | |||
| Total debt | $38049 | |||
| Total liabilities | $53278 | $58111 | $64140 | $75393 |
| Shareholders' equity | ||||
| Retained earnings | $49649 | $63540 | $70989 | $57157 |
| Other shareholder equity | -$3608 | -$4798 | -$4187 | -$1419 |
| Total shareholder equity | $46667 | $59342 | $67655 | $56598 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | ||||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 1 Feb 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $46660 | $51828 | $49898 | |
| Cost of revenue | $15486 | $14400 | ||
| Gross Profit | $34640 | $36342 | $35498 | |
| Operating activities | ||||
| Research & development | $9996 | $8548 | ||
| Selling, general & administrative | $14253 | $14093 | ||
| Total operating expenses | $21942 | $39735 | $37711 | |
| Operating income | $12093 | $12187 | ||
| Income from continuing operations | ||||
| EBIT | $12084 | $12187 | ||
| Income tax expense | $551 | $1416 | $1807 | |
| Interest expense | -$497 | -$869 | ||
| Net income | ||||
| Net income | $14850 | $6955 | $8072 | |
| Income (for common shares) | $6955 | $8072 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$4480 | -$4106 | -$899 | $5596 |
| Financing activities | ||||
| Dividends paid | -$7624 | -$7624 | -$5207 | -$7255 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$8746 | -$8364 | -$5164 | -$14278 |
| Effect of exchange rate | $16 | -$160 | -$126 | $100 |
| Change in cash and equivalents | $216 | -$5490 | -$3924 | $5876 |
| (in millions $) | 31 Jan 2024 | 1 Feb 2023 | 2 Feb 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $6955 | $24021 | $8072 | |
| Operating activities | ||||
| Depreciation | $7181 | $6113 | $5550 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $14236 | $14546 | $13650 | |
| Investing activities | ||||
| Capital expenditures | -$2672 | -$2971 | -$1275 | |
| Investments | -$922 | |||
| Total cash flows from investing | $5596 | $1468 | $4733 | -$13182 |
| Financing activities | ||||
| Dividends paid | -$7255 | -$6987 | ||
| Sale and purchase of stock | ||||
| Net borrowings | $7067 | $801 | $7072 | |
| Total cash flows from financing | -$14278 | -$20562 | -$16264 | -$2208 |
| Effect of exchange rate | $100 | $286 | ||
| Change in cash and equivalents | $5876 | -$9356 | $16766 | -$1454 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.14 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |